1
|
Bourdon M, Peigné M, Maignien C, de Villardi de Montlaur D, Solignac C, Darné B, Languille S, Bendifallah S, Santulli P. Impact of Endometriosis Surgery on In Vitro Fertilization/Intracytoplasmic Sperm Injection Outcomes: a Systematic Review and Meta-analysis. Reprod Sci 2024; 31:1431-1455. [PMID: 38168857 DOI: 10.1007/s43032-023-01421-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2023] [Accepted: 12/04/2023] [Indexed: 01/05/2024]
Abstract
Endometriosis-related infertility remains a therapeutic challenge. A burning issue in this field of research is determining whether pre-assisted reproductive technology (ART) surgery may be of some benefit in terms of reproductive outcomes. This systematic review and meta-analysis aimed at comparing ongoing pregnancy rates (OPR) and/or live birth rates (LBR) in patients who underwent endometriosis surgery before ART (IVF/ICSI) in comparison with patients who underwent first-line ART (IVF/ICSI). Searches were conducted from January 1990 to June 2021 on PubMed, Embase, and Cochrane Library using the following search terms: endometriosis, surgery, reproductive outcomes, and IVF/ICSI. The primary outcomes were OPR or LBR. A total of 19 studies were included in the meta-analysis. No statistically significant differences in LBR [0.91[0.63, 1.30]; I2 = 66%; n = 11], OPR [1.28[0.66, 2.49]; I2 = 60%; n = 3], and early pregnancy loss rate [0.88[0.62, 1.25]; I2 = 0%; n = 7] per cycle were found when comparing patients who underwent endometriosis surgery before IVF/ICSI and those who did not. After the exclusion of the studies with high risks of bias, the LBR per cycle was significantly reduced in the case of surgical treatment before IVF/ICSI [0.53[0.33, 0.86]; I2 = 30%; n = 4]. These data urge the clinician to carefully weigh the pros and cons before referring infertile patients with endometriosis to surgery before IVF, highlighting the key role of multidisciplinary referral centers.
Collapse
Affiliation(s)
- M Bourdon
- Department of Gynecology Obstetrics II and Reproductive Medicine (Professor Chapron), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Université de Paris Cité, Faculté de Santé, Paris, France
- Department 3I "Infection, Immunité Et Inflammation", Institut Cochin, INSERM U1016, Paris, France
| | - M Peigné
- Department of Reproductive Médecine and Fertility Preservation, AP-HP, Hopital Jean Verdier, Université Sorbonne Paris Nord, Faculté de Santé, Bondy, France
| | - C Maignien
- Department of Gynecology Obstetrics II and Reproductive Medicine (Professor Chapron), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Université de Paris Cité, Faculté de Santé, Paris, France
| | | | - C Solignac
- Gedeon Richter France, 75008, Paris, France
| | - B Darné
- Monitoring Force, 78600, Maisons-Laffitte, France
| | - S Languille
- Monitoring Force, 78600, Maisons-Laffitte, France
| | - S Bendifallah
- Department of Gynecology Obstetrics and Reproductive Medicine, AP-HP, Hôpital Tenon, Hôpitaux Universitaires Est Parisien, Faculté de Santé, Paris, France
| | - Pietro Santulli
- Department of Gynecology Obstetrics II and Reproductive Medicine (Professor Chapron), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Université de Paris Cité, Faculté de Santé, Paris, France.
- Department 3I "Infection, Immunité Et Inflammation", Institut Cochin, INSERM U1016, Paris, France.
| |
Collapse
|
2
|
Bourdon M, Guihard C, Maignien C, Patrat C, Guibourdenche J, Chapron C, Santulli P. Intra-individual variability of serum progesterone levels on the day of frozen blastocyst transfer in hormonal replacement therapy cycles. Hum Reprod 2024; 39:742-748. [PMID: 38332539 DOI: 10.1093/humrep/deae015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2023] [Revised: 01/11/2024] [Indexed: 02/10/2024] Open
Abstract
STUDY QUESTION Is there a significant intra-individual variability of serum progesterone levels on the day of single blastocyst Hormone Replacement Therapy-Frozen Embryo Transfer (HRT-FET) between two consecutive cycles? SUMMARY ANSWER No significant intra-individual variability of serum progesterone (P) levels was noted between two consecutive HRT-FET cycles. WHAT IS KNOWN ALREADY In HRT-FET cycles, a minimum P level on the day of embryo transfer is necessary to optimise reproductive outcomes. In a previous study by our team, a threshold of 9.8 ng/ml serum P was identified as significantly associated with the live birth rates in single autologous blastocyst transfers under HRT using micronized vaginal progesterone (MVP). Such patients may benefit from an intensive luteal phase support (LPS) using other routes of P administration in addition to MVP. A crucial question in the way towards individualising LPS is whether serum P measurements are reproducible for a given patient in consecutive HRT-FET cycles, using the same LPS. STUDY DESIGN, SIZE, DURATION We conducted an observational cohort study at the university-based reproductive medicine centre of our institution focusing on women who underwent at least two consecutive single autologous blastocyst HRT-FET cycles between January 2019 and March 2020. PARTICIPANTS/MATERIALS, SETTING, METHODS Patients undergoing two consecutive single autologous blastocyst HRT-FET cycles using exogenous oestradiol and vaginal micronized progesterone for endometrial preparation were included. Serum progesterone levels were measured on the morning of the Frozen Embryo Transfer (FET), by a single laboratory. The two measurements of progesterone levels performed on the day of the first (FET1) and the second FET (FET2) were compared to evaluate the intra-individual variability of serum P levels. Paired statistical analyses were performed, as appropriate. MAIN RESULTS AND THE ROLE OF CHANCE Two hundred and sixty-four patients undergoing two consecutive single autologous blastocyst HRT-FET were included. The mean age of the included women was 35.0 ± 4.2 years. No significant intra-individual variability was observed between FET1 and FET2 (mean progesterone level after FET1: 13.4 ± 5.1 ng/ml vs after FET2: 13.9 ± 5.0; P = 0.08). The characteristics of the embryo transfers were similar between the first and the second FET. Forty-nine patients (18.6%) had discordant progesterone levels (defined as one progesterone measurement > and one ≤ to the threshold of 9.8 ng/ml) between FET1 and FET2. There were 37/264 women (14.0%) who had high intra-individual variability (defined as a difference in serum progesterone values >75th percentile (6.0 ng/ml)) between FET1 and FET2. No specific clinical parameter was associated with a high intra-individual variability nor a discordant P measurement. LIMITATIONS, REASONS FOR CAUTION This study is limited by its retrospective design. Moreover, only women undergoing autologous blastocyst HRT-FET with MVP were included, thereby limiting the extrapolation of the study findings to other routes of P administration and other kinds of endometrial preparation for FET. WIDER IMPLICATIONS OF THE FINDINGS No significant intra-individual variability was noted. The serum progesterone level appeared to be reproducible in >80% of cases. These findings suggest that the serum progesterone level measured on the day of the first transfer can be used to individualize luteal phase support in subsequent cycles. STUDY FUNDING/COMPETING INTEREST(S) No funding or competing interests. TRIAL REGISTRATION NUMBER N/A.
Collapse
Affiliation(s)
- M Bourdon
- Faculté de Médecine, Université de Paris Cité, Paris, France
- Department of Gynecology Obstetrics II and Reproductive Medicine (Professor Chapron), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
- Department "Development, Reproduction and Cancer", Cochin Institute, INSERM U1016, Paris, France
| | - C Guihard
- Faculté de Médecine, Université de Paris Cité, Paris, France
- Department of Gynecology Obstetrics II and Reproductive Medicine (Professor Chapron), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
| | - C Maignien
- Faculté de Médecine, Université de Paris Cité, Paris, France
- Department of Gynecology Obstetrics II and Reproductive Medicine (Professor Chapron), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
| | - C Patrat
- Faculté de Médecine, Université de Paris Cité, Paris, France
- Department "Development, Reproduction and Cancer", Cochin Institute, INSERM U1016, Paris, France
- Department of Reproductive Biology-CECOS (Professor Patrat), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
| | - J Guibourdenche
- Faculté de Médecine, Université de Paris Cité, Paris, France
- Department of Biological Endocrinology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
| | - C Chapron
- Faculté de Médecine, Université de Paris Cité, Paris, France
- Department of Gynecology Obstetrics II and Reproductive Medicine (Professor Chapron), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
- Department "Development, Reproduction and Cancer", Cochin Institute, INSERM U1016, Paris, France
| | - P Santulli
- Faculté de Médecine, Université de Paris Cité, Paris, France
- Department of Gynecology Obstetrics II and Reproductive Medicine (Professor Chapron), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
- Department "Development, Reproduction and Cancer", Cochin Institute, INSERM U1016, Paris, France
| |
Collapse
|
3
|
Maignien C, Bourdon M, Parpex G, Ferreux L, Patrat C, Bordonne C, Marcellin L, Chapron C, Santulli P. Endometriosis-related infertility: severe pain symptoms do not impact assisted reproductive technology outcomes. Hum Reprod 2024; 39:346-354. [PMID: 38142239 DOI: 10.1093/humrep/dead252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2023] [Revised: 11/06/2023] [Indexed: 12/25/2023] Open
Abstract
STUDY QUESTION Do severe endometriosis-related painful symptoms impact ART live birth rates? SUMMARY ANSWER Severe pain symptoms are not associated with reduced ART live birth rates in endometriosis patients. WHAT IS KNOWN ALREADY ART is currently recognized as one of the main therapeutic options to manage endometriosis-related infertility. Presently, no data exist in the literature regarding the association between the core symptom of the disease, e.g. pain and ART reproductive outcomes. STUDY DESIGN, SIZE, DURATION Observational cohort study of 354 endometriosis patients, who underwent ART at a tertiary care university hospital, between October 2014 and October 2021. Diagnosis of endometriosis was based on published imaging criteria using transvaginal sonography and magnetic resonance imaging, and histologically confirmed in women who had a previous history of endometriosis surgery (n = 127, 35.9%). PARTICIPANTS/MATERIALS, SETTING, METHODS The intensity of painful symptoms related to dysmenorrhea (DM), dyspareunia (DP), noncyclic chronic pelvic pain, gastrointestinal (GI) pain, or lower urinary tract pain was evaluated using a 10-point visual analog scale (VAS), before ART. Severe pain was defined as having a VAS of 7 or higher for at least one symptom. The main outcome measure was the cumulative live birth rate (CLBR) per patient. We analyzed the impact of endometriosis-related painful symptoms on ART live births using univariable and multivariate analysis. MAIN RESULTS AND THE ROLE OF CHANCE Three hundred and fifty-four endometriosis patients underwent 711 ART cycles. The mean age of the population was 33.8 ± 3.7 years, and the mean duration of infertility was 3.6 ± 2.1 years. The distribution of the endometriosis phenotypes was 3.1% superficial endometriosis, 8.2% ovarian endometrioma, and 88.7% deep infiltrating endometriosis. The mean VAS scores for DM, DP, and GI pain symptoms were 6.6 ± 2.7, 3.4 ± 3.1, and 3.1 ± 3.6, respectively. Two hundred and forty-two patients (68.4%) had severe pain symptoms. The CLBR per patient was 63.8% (226/354). Neither the mean VAS scores for the various painful symptoms nor the proportion of patients displaying severe pain differed significantly between patients who had a live birth and those who had not, based on univariate and multivariate analyses (P = 0.229). The only significant factors associated with negative ART live births were age >35 years (P < 0.001) and anti-Müllerian hormone levels <1.2 ng/ml (P < 0.001). LIMITATIONS, REASONS FOR CAUTION The diagnosis of endometriosis was based on imaging rather than surgery. This limitation is, however, inherent to the design of most studies on endometriosis patients reverting to ART first. WIDER IMPLICATIONS OF THE FINDINGS Rather than considering a single argument such as pain, the decision-making process for choosing between ART and surgery in infertile endometriosis patients should be based on a multitude of aspects, including the patient's choice, the associated infertility factors, the endometriosis phenotypes, and the efficiency of medical therapies in regard to pain symptoms, through an individualized approach guided by a multidisciplinary team of experts. STUDY FUNDING/COMPETING INTEREST(S) No funding; no conflict of interest. TRIAL REGISTRATION NUMBER N/A.
Collapse
Affiliation(s)
- C Maignien
- Faculté de Santé, Université de Paris, Paris, France
- Department of Gynecology Obstetrics II and Reproductive Medicine (Professor Chapron), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
| | - M Bourdon
- Faculté de Santé, Université de Paris, Paris, France
- Department of Gynecology Obstetrics II and Reproductive Medicine (Professor Chapron), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
- Department "Development, Reproduction and Cancer", Cochin Institute, INSERM U1016 (Professor Batteux), Paris, France
| | - G Parpex
- Faculté de Santé, Université de Paris, Paris, France
- Department of Gynecology Obstetrics II and Reproductive Medicine (Professor Chapron), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
- Department "Development, Reproduction and Cancer", Cochin Institute, INSERM U1016 (Professor Batteux), Paris, France
| | - L Ferreux
- Faculté de Santé, Université de Paris, Paris, France
- Department of Reproductive Biology (Professor Patrat), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
| | - C Patrat
- Faculté de Santé, Université de Paris, Paris, France
- Department of Reproductive Biology (Professor Patrat), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
| | - C Bordonne
- Faculté de Santé, Université de Paris, Paris, France
- Department of Gynecology Obstetrics II and Reproductive Medicine (Professor Chapron), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
- Department of Radiology (Professor Dion), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Hôtel-Dieu, Paris, France
| | - L Marcellin
- Faculté de Santé, Université de Paris, Paris, France
- Department of Gynecology Obstetrics II and Reproductive Medicine (Professor Chapron), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
- Department "Development, Reproduction and Cancer", Cochin Institute, INSERM U1016 (Professor Batteux), Paris, France
| | - C Chapron
- Faculté de Santé, Université de Paris, Paris, France
- Department of Gynecology Obstetrics II and Reproductive Medicine (Professor Chapron), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
- Department "Development, Reproduction and Cancer", Cochin Institute, INSERM U1016 (Professor Batteux), Paris, France
| | - P Santulli
- Faculté de Santé, Université de Paris, Paris, France
- Department of Gynecology Obstetrics II and Reproductive Medicine (Professor Chapron), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
- Department "Development, Reproduction and Cancer", Cochin Institute, INSERM U1016 (Professor Batteux), Paris, France
| |
Collapse
|
4
|
Bourdon M, Antoine V, Combes U, Maitrot-Mantelet L, Marcellin L, Maignien C, Chapron C, Santulli P. Severe pelvic pain is associated with sexual abuse experienced during childhood and/or adolescence irrespective of the presence of endometriosis. Hum Reprod 2023; 38:1499-1508. [PMID: 37308317 DOI: 10.1093/humrep/dead119] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2023] [Revised: 03/30/2023] [Indexed: 06/14/2023] Open
Abstract
STUDY QUESTION Is endometriosis associated with childhood and/or adolescent sexual abuse? SUMMARY ANSWER Endometriosis is not associated with a history of sexual abuse, unlike the presence of severe pelvic pain. WHAT IS KNOWN ALREADY Several studies have highlighted a link between pelvic pain and sexual abuse during childhood/adolescence. Moreover, an inflammatory state has been described in patients with a history of childhood maltreatment. Given that inflammation and pelvic pain are two entities often encountered with endometriosis, several teams have investigated whether endometriosis is associated with abuse during childhood/adolescence. However, the results are conflicting, and the link between sexual abuse and the presence of endometriosis and/or pain is hard to disentangle. STUDY DESIGN, SIZE, DURATION A survey nested in a cohort study of women surgically explored for benign gynecological indications at our institution between January 2013 and January 2017. For each patient, a standardized questionnaire was completed during a face-to-face interview with the surgeon in the month preceding the surgery. Pelvic pain symptoms (dysmenorrhea, deep dyspareunia, non-cyclic chronic pelvic pain, and gastrointestinal or lower urinary tract symptoms) and their intensities were assessed with a 10 cm visual analog scale (VAS). Pain was considered to be severe when the VAS score was ≥7. PARTICIPANTS/MATERIALS, SETTING, METHODS A 52-question survey was sent in September of 2017 to evaluate abuses, especially sexual abuse during childhood and/or adolescence, and the psychological state during childhood and adolescence. The survey was structured to cover the following sections: (i) abuses and other life events during childhood and adolescence; (ii) puberty and body changes; (iii) onset of sexuality; and (iv) family relationships during childhood and adolescence. The patients were divided into groups according to whether or not they exhibited histologically proven endometriosis. Statistical analyses were conducted using univariate and multivariate logistic regression models. MAIN RESULTS AND THE ROLE OF CHANCE Two hundred and seventy-one patients answered all the questions of the survey: 168 with (endometriosis group) and 103 without endometriosis (control group). The mean ± SD overall population age was 32.2 ± 5.1 years. There were 136 (80.9%) and 48 (46.6%) women who experienced at least one severe pelvic pain symptom in the endometriosis and the control groups, respectively (P < 0.001). No differences were found between the two study groups regarding the following characteristics: (i) a history of sexual, physical, or emotional abuse; (ii) a history of abandonment or bereavement; (iii) the psychological state regarding puberty; and (iv) the family relationships. After multivariable analysis, we found no significant association between endometriosis and a history of sexual abuse during childhood and/or adolescence (P = 0.550). However, the presence of at least one severe pelvic pain symptom was independently associated with a history of sexual abuse (odds ratio = 3.6, 95% CI (1.2-10.4)). LIMITATIONS, REASONS FOR CAUTION Evaluation of the psychological state during childhood and/or adolescence can be subject to recall bias. In addition, selection bias is also a possibility given that some of the patients surveyed did not return the questionnaire. WIDER IMPLICATIONS OF THE FINDINGS Severe gynecological painful symptoms in women with or without histologically proven endometriosis may be linked to sexual abuse experienced during childhood and/or adolescence. Patient questioning about painful symptoms and abuses is important to provide comprehensive care to the patients, from a psychological to a somatic point of view. STUDY FUNDING/COMPETING INTEREST(S) No funding or competing interests. TRIAL REGISTRATION NUMBER N/A.
Collapse
Affiliation(s)
- M Bourdon
- Department of Gynaecology, Obstetrics II and Reproductive Medicine, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
- Faculté de Médecine, Université Paris-Cité, Paris, France
- Department 3I "Infection, Immunité et inflammation", Institut Cochin, INSERM U1016, Paris, France
| | - V Antoine
- Department of Gynaecology, Obstetrics II and Reproductive Medicine, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
| | - U Combes
- Department of Gynaecology, Obstetrics II and Reproductive Medicine, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
| | - L Maitrot-Mantelet
- Department of Gynaecology, Obstetrics II and Reproductive Medicine, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
| | - L Marcellin
- Department of Gynaecology, Obstetrics II and Reproductive Medicine, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
- Faculté de Médecine, Université Paris-Cité, Paris, France
- Department 3I "Infection, Immunité et inflammation", Institut Cochin, INSERM U1016, Paris, France
| | - C Maignien
- Department of Gynaecology, Obstetrics II and Reproductive Medicine, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
| | - C Chapron
- Department of Gynaecology, Obstetrics II and Reproductive Medicine, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
- Faculté de Médecine, Université Paris-Cité, Paris, France
- Department 3I "Infection, Immunité et inflammation", Institut Cochin, INSERM U1016, Paris, France
| | - P Santulli
- Department of Gynaecology, Obstetrics II and Reproductive Medicine, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
- Faculté de Médecine, Université Paris-Cité, Paris, France
- Department 3I "Infection, Immunité et inflammation", Institut Cochin, INSERM U1016, Paris, France
| |
Collapse
|
5
|
Bourdon M, Ouazana M, Maignien C, Pocate Cheriet K, Patrat C, Marcellin L, Gonnot J, Cervantes C, Laviron E, Blanchet V, Chapron C, Santulli P. Embryo transfer learning using medical simulation tools: a comparison of two embryo transfer simulators. J Gynecol Obstet Hum Reprod 2023; 52:102542. [PMID: 36682581 DOI: 10.1016/j.jogoh.2023.102542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2022] [Revised: 10/11/2022] [Accepted: 01/18/2023] [Indexed: 01/22/2023]
Abstract
INTRODUCTION Embryo transfer(ET) is one of the main procedures to become pregnant by assisted reproductive technology(ART). Simulation training is a way to improve the skills of clinicians. The objective of this study was to evaluate the interest of trainees in learning embryo transfer using simulators. MATERIAL AND METHODS An observational study was conducted at the University hospital-based research center. Trainees, comprising midwives and resident or graduated gynecologists, who attended the medical training for infertility and ART in June 2019, were included. They trained on two ET simulators (Simulator A and B) and complete an anonymously online questionnaire. A sub-group analysis focusing on graduated gynecologists not performing ET in current practice, was performed. RESULTS Thirty-two trainees were included. Trainees felt that ET simulators should be used in medical education to promote learning how to perform the ET procedure (n=26, 81.3% for Simulator A and n=21, 65.5% for Simulator B; p=0.31). The use of both simulators improved the level of self-confidence (81.3% and 75.0% respectively; p=0.55). Significant differences in the global and in the subgroup analysis (n=24) in favor of Simulator A were observed regarding learning the precision of the ET procedure (p<0.01), the pathway to introduce the catheter into the uterine cavity (p<0.05), and the guidance for proper placement of the catheter into the uterine cavity (p=0.03). In the subgroup analysis of graduated gynecologists not performing ET in current practice, Simulator A was found more realistic for the visualization of the introduction of the catheter into the uterine cavity (p=0.01) and more useful to learn about difficult cases (p=0.03). CONCLUSION Students expressed a high level of interest in ET simulators to improve their skills. Although the simulators displayed some differences regarding learning the precision of the ET procedure, both improved the level of self-confidence. This new learning method needs to be further developed in order to offer to trainees the most realistic simulators. TRIAL REGISTRATION This study was approved for publication by the Ethics Review Committee of the Cochin University Hospital (CLEP) (n° AAA-2020-08016) retrospectively registered.
Collapse
Affiliation(s)
- Mathilde Bourdon
- Université de Paris, Faculty of Medicine, Paris, France; Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital universitaire Paris Centre (HUPC), France; Department of Gynaecology Obstetrics II and Reproductive Medicine, Centre Hospitalier Universitaire (CHU) Cochin, Paris, France; Department 3I « Infection, Immunité et inflammation", Institut Cochin, INSERM U1016, France
| | - Marion Ouazana
- Université de Paris, Faculty of Medicine, Paris, France; Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital universitaire Paris Centre (HUPC), France; Department of Gynaecology Obstetrics II and Reproductive Medicine, Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
| | - Chloe Maignien
- Université de Paris, Faculty of Medicine, Paris, France; Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital universitaire Paris Centre (HUPC), France; Department of Gynaecology Obstetrics II and Reproductive Medicine, Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
| | - Khaled Pocate Cheriet
- Université de Paris, Faculty of Medicine, Paris, France; Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital universitaire Paris Centre (HUPC), France; Department of histology -embryology and reproductive biology, Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
| | - Catherine Patrat
- Université de Paris, Faculty of Medicine, Paris, France; Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital universitaire Paris Centre (HUPC), France; Department of histology -embryology and reproductive biology, Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
| | - Louis Marcellin
- Université de Paris, Faculty of Medicine, Paris, France; Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital universitaire Paris Centre (HUPC), France; Department of Gynaecology Obstetrics II and Reproductive Medicine, Centre Hospitalier Universitaire (CHU) Cochin, Paris, France; Department 3I « Infection, Immunité et inflammation", Institut Cochin, INSERM U1016, France
| | - Juia Gonnot
- Université de Paris, Faculty of Medicine, Paris, France; Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital universitaire Paris Centre (HUPC), France; Department of Gynaecology Obstetrics II and Reproductive Medicine, Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
| | - Celie Cervantes
- Université de Paris, Faculty of Medicine, Paris, France; Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital universitaire Paris Centre (HUPC), France; Department of Gynaecology Obstetrics II and Reproductive Medicine, Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
| | - Emmanuelle Laviron
- Université de Paris, Faculty of Medicine, Paris, France; Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital universitaire Paris Centre (HUPC), France; Department of Gynaecology Obstetrics II and Reproductive Medicine, Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
| | - Valerie Blanchet
- Université de Paris, Faculty of Medicine, Paris, France; Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital universitaire Paris Centre (HUPC), France; Department of Gynaecology Obstetrics II and Reproductive Medicine, Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
| | - Charles Chapron
- Université de Paris, Faculty of Medicine, Paris, France; Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital universitaire Paris Centre (HUPC), France; Department of Gynaecology Obstetrics II and Reproductive Medicine, Centre Hospitalier Universitaire (CHU) Cochin, Paris, France; Department 3I « Infection, Immunité et inflammation", Institut Cochin, INSERM U1016, France
| | - Pietro Santulli
- Université de Paris, Faculty of Medicine, Paris, France; Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital universitaire Paris Centre (HUPC), France; Department of Gynaecology Obstetrics II and Reproductive Medicine, Centre Hospitalier Universitaire (CHU) Cochin, Paris, France; Department 3I « Infection, Immunité et inflammation", Institut Cochin, INSERM U1016, France.
| |
Collapse
|
6
|
Marcellin L, Bourdon M, Houdre D, Maignien C, Chardonnet AG, Borghese B, Mantelet LM, Santulli P, Chapron C. Decrease of dysmenorrhoea with hormonal treatment is a marker of endometriosis severity. Reprod Biomed Online 2023; 46:856-864. [PMID: 36959070 DOI: 10.1016/j.rbmo.2023.01.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2022] [Revised: 12/27/2022] [Accepted: 01/06/2023] [Indexed: 01/13/2023]
Abstract
RESEARCH QUESTION Is a decrease in dysmenorrhoea after suppressive hormonal therapy a marker of the endometriosis phenotype and of greater disease severity? DESIGN Retrospective observational cohort study conducted in a French university hospital, between January 2004 and December 2019. Non-pregnant women aged younger than 42 years, who tested for dysmenorrhoea relief after suppressive hormonal therapy before surgery, and who had histological confirmation of endometriosis, were included. The comparisons were carried out according to the results of the suppressive hormonal test. RESULTS Of the 578 histologically proven endometriosis patients with preoperative pain symptoms, the rate of dysmenorrhoea decrease after suppressive hormonal therapy was 88.2% (n = 510). These patients had a higher incidence of deep infiltrating endometriosis (DIE) intestinal lesions (45.7% [233/510] versus 30.8% [21/68], P = 0.01) and an increased rate of multiple DIE lesions (two or more) (72.8% [287/394] versus 56.4% [22/39], P = 0.02). After multivariate analysis, decrease of dysmenorrhoea after suppressive hormonal therapy remained significantly associated with the severe DIE phenotype (adjusted OR 3.9, 95% CI 2.0 to 7.6, P < 0.001). CONCLUSION In women with endometriosis, a decrease of dysmenorrhoea after suppressive hormonal therapy is associated with the DIE phenotype and is a marker of greater severity.
Collapse
Affiliation(s)
- Louis Marcellin
- Université Paris Cité, Faculté de Santé, Faculté de Médecine Paris Centre, Paris, France; Service de Gynécologie-Obstétrique II et de Médecine de la Reproduction, AP-HP, Centre Hospitalier Universitaire (CHU) Cochin, 75014, Paris, France; Department 'Development, Reproduction and Cancer', Institut Cochin, INSERM U1016, Paris, France.
| | - Mathilde Bourdon
- Université Paris Cité, Faculté de Santé, Faculté de Médecine Paris Centre, Paris, France; Service de Gynécologie-Obstétrique II et de Médecine de la Reproduction, AP-HP, Centre Hospitalier Universitaire (CHU) Cochin, 75014, Paris, France; Department 'Development, Reproduction and Cancer', Institut Cochin, INSERM U1016, Paris, France
| | - Doriane Houdre
- Université Paris Cité, Faculté de Santé, Faculté de Médecine Paris Centre, Paris, France; Service de Gynécologie-Obstétrique II et de Médecine de la Reproduction, AP-HP, Centre Hospitalier Universitaire (CHU) Cochin, 75014, Paris, France
| | - Chloe Maignien
- Université Paris Cité, Faculté de Santé, Faculté de Médecine Paris Centre, Paris, France; Service de Gynécologie-Obstétrique II et de Médecine de la Reproduction, AP-HP, Centre Hospitalier Universitaire (CHU) Cochin, 75014, Paris, France; Department 'Development, Reproduction and Cancer', Institut Cochin, INSERM U1016, Paris, France
| | - Antoine Gaudet Chardonnet
- Université Paris Cité, Faculté de Santé, Faculté de Médecine Paris Centre, Paris, France; Service de Gynécologie-Obstétrique II et de Médecine de la Reproduction, AP-HP, Centre Hospitalier Universitaire (CHU) Cochin, 75014, Paris, France
| | - Bruno Borghese
- Université Paris Cité, Faculté de Santé, Faculté de Médecine Paris Centre, Paris, France; Service de Gynécologie-Obstétrique II et de Médecine de la Reproduction, AP-HP, Centre Hospitalier Universitaire (CHU) Cochin, 75014, Paris, France; Department 'Development, Reproduction and Cancer', Institut Cochin, INSERM U1016, Paris, France
| | - Lorraine Maitrot Mantelet
- Université Paris Cité, Faculté de Santé, Faculté de Médecine Paris Centre, Paris, France; Service de Gynécologie-Obstétrique II et de Médecine de la Reproduction, AP-HP, Centre Hospitalier Universitaire (CHU) Cochin, 75014, Paris, France
| | - Pietro Santulli
- Université Paris Cité, Faculté de Santé, Faculté de Médecine Paris Centre, Paris, France; Service de Gynécologie-Obstétrique II et de Médecine de la Reproduction, AP-HP, Centre Hospitalier Universitaire (CHU) Cochin, 75014, Paris, France; Department 'Development, Reproduction and Cancer', Institut Cochin, INSERM U1016, Paris, France
| | - Charles Chapron
- Université Paris Cité, Faculté de Santé, Faculté de Médecine Paris Centre, Paris, France; Service de Gynécologie-Obstétrique II et de Médecine de la Reproduction, AP-HP, Centre Hospitalier Universitaire (CHU) Cochin, 75014, Paris, France; Department 'Development, Reproduction and Cancer', Institut Cochin, INSERM U1016, Paris, France
| |
Collapse
|
7
|
Maignien C, Bourdon M, Marcellin L, Guibourdenche J, Chargui A, Patrat C, Plu-Bureau G, Chapron C, Santulli P. Clinical factors associated with low serum progesterone levels on the day of frozen blastocyst transfer in hormonal replacement therapy cycles. Hum Reprod 2022; 37:2570-2577. [PMID: 36125015 DOI: 10.1093/humrep/deac199] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2022] [Revised: 08/12/2022] [Indexed: 11/14/2022] Open
Abstract
STUDY QUESTION Which factors are associated with low serum progesterone (P) levels on the day of frozen embryo transfer (FET), in HRT cycles? SUMMARY ANSWER BMI, parity and non-European geographic origin are factors associated with low serum P levels on the day of FET in HRT cycles. WHAT IS KNOWN ALREADY The detrimental impact of low serum P concentrations on HRT-FET outcomes is commonly recognized. However, the factors accounting for P level disparities among patients receiving the same luteal phase support treatment remain to be elucidated, to help clinicians predicting which subgroups of patients would benefit from a tailored P supplementation. STUDY DESIGN, SIZE, DURATION Observational cohort study with 915 patients undergoing HRT-FET at a tertiary care university hospital, between January 2019 and March 2020. PARTICIPANTS/MATERIALS, SETTING, METHODS Patients undergoing single autologous blastocyst FET under HRT using exogenous estradiol and vaginal micronized progesterone for endometrial preparation. Women were only included once during the study period. The serum progesterone level was measured in the morning of the FET, in a single laboratory. Independent factors associated with low serum P levels (defined as ≤9.8 ng/ml, according to a previous published study) were analyzed using univariate and multivariate logistic regression models. MAIN RESULTS AND THE ROLE OF CHANCE Two hundred and twenty-six patients (24.7%) had a low serum P level, on the day of the FET. Patients with a serum P level ≤9.8 ng/ml had a lower live birth rate (26.1% vs 33.2%, P = 0.045) and a higher rate of early miscarriage (35.2% vs 21.5%, P = 0.008). Univariate analysis showed that BMI (P < 0.001), parity (P = 0.001), non-European geographic origin (P = 0.001), the duration of infertility (P = 0.018) and the use of oral estradiol for endometrial preparation (P = 0.009) were significantly associated with low serum P levels. Moreover, the proportion of active smokers was significantly lower in the 'low P concentrations' group (P = 0.002). After multivariate analysis, BMI (odds ratio (OR) 1.06 95% CI (1.02-1.11), P = 0.002), parity (OR 1.32 95% CI (1.04-1.66), P = 0.022), non-European geographic origin (OR 1.70 95% CI (1.21-2.39), P = 0.002) and active smoking (OR 0.43 95% CI (0.22-0.87), P = 0.018) remained independent factors associated with serum P levels ≤9.8 ng/ml. LIMITATIONS, REASONS FOR CAUTION The main limitation of this study is its observational design, leading to a risk of selection and confusion bias that cannot be ruled out, although a multivariable analysis was performed to minimize this. WIDER IMPLICATIONS OF THE FINDINGS Extrapolation of our results to other laboratories, or other routes and/or doses of administering progesterone also needs to be validated. There is urgent need for future research on clinical factors affecting P concentrations and the underlying pathophysiological mechanisms, to help clinicians in predicting which subgroups of patients would benefit from individualized luteal phase support. STUDY FUNDING/COMPETING INTEREST(S) No funding/no conflicts of interest. TRIAL REGISTRATION NUMBER N/A.
Collapse
Affiliation(s)
- C Maignien
- Faculté de Santé, Université de Paris, Paris, France.,Department of Gynecology Obstetrics II and Reproductive Medicine, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
| | - M Bourdon
- Faculté de Santé, Université de Paris, Paris, France.,Department of Gynecology Obstetrics II and Reproductive Medicine, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France.,Department "Development, Reproduction and Cancer", Cochin Institute, INSERM U1016 (Professor Batteux), Paris, France
| | - L Marcellin
- Faculté de Santé, Université de Paris, Paris, France.,Department of Gynecology Obstetrics II and Reproductive Medicine, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France.,Department "Development, Reproduction and Cancer", Cochin Institute, INSERM U1016 (Professor Batteux), Paris, France
| | - J Guibourdenche
- Faculté de Santé, Université de Paris, Paris, France.,Department of Biological Endocrinology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
| | - A Chargui
- Faculté de Santé, Université de Paris, Paris, France.,Department of Histology and Reproductive Biology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
| | - C Patrat
- Faculté de Santé, Université de Paris, Paris, France.,Department of Histology and Reproductive Biology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
| | - G Plu-Bureau
- Faculté de Santé, Université de Paris, Paris, France.,Department of Gynecology Obstetrics II and Reproductive Medicine, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France.,Equipe EPOPE, INSERM U1153, Paris, France
| | - C Chapron
- Faculté de Santé, Université de Paris, Paris, France.,Department of Gynecology Obstetrics II and Reproductive Medicine, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France.,Department "Development, Reproduction and Cancer", Cochin Institute, INSERM U1016 (Professor Batteux), Paris, France
| | - P Santulli
- Faculté de Santé, Université de Paris, Paris, France.,Department of Gynecology Obstetrics II and Reproductive Medicine, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France.,Department "Development, Reproduction and Cancer", Cochin Institute, INSERM U1016 (Professor Batteux), Paris, France
| |
Collapse
|
8
|
Bourdon M, Dahan Y, Maignien C, Patrat C, Bordonne C, Marcellin L, Chapron C, Santulli P. Influence of endometrioma size on assisted reproductive technology outcomes. Reprod Biomed Online 2022; 45:1237-1246. [DOI: 10.1016/j.rbmo.2022.08.097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2022] [Revised: 08/02/2022] [Accepted: 08/05/2022] [Indexed: 11/24/2022]
|
9
|
Maignien C, Bourdon M, Marcellin L, Guibourdenche J, Chargui A, Patrat C, Plu-Bureau G, Chapron C, Santulli P. O-245 Clinical factors associated with low serum progesterone on the day of frozen blastocyst transfer in hormonal replacement therapy cycles. Hum Reprod 2022. [DOI: 10.1093/humrep/deac106.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Study question
Which factors are associated with low serum progesterone (P) levels on the day of frozen embryo transfer (FET), in hormonal replacement therapy (HRT) cycles?
Summary answer
Body Mass Index (BMI), parity, and non-European geographic origin are factors associated with low serum P levels on the day of FET in HRT cycles.
What is known already
While the detrimental impact of low serum P concentrations on HRT-FET outcomes is unanimously recognized, the factors accounting for P levels disparities among patients receiving the same luteal phase support treatment remain to be elucidated, in order to help clinicians predicting which subgroups of patients would benefit from a tailored P supplementation.
Study design, size, duration
Observational cohort study with 915 patients undergoing HRT-FET at a tertiary care university hospital, between January 2019 and March 2020.
Participants/materials, setting, methods
Patients undergoing single autologous blastocyst FET under HRT using exogenous estradiol and vaginal micronized progesterone for endometrial preparation. Women were only included once during the study period. The serum progesterone level was measured in the morning of the FET, in a single laboratory. Independent factors associated with low serum P levels (defined as ≤ 9.8 ng/mL, according to a previous published study) were analyzed using univariate and multivariate logistic regression models.
Main results and the role of chance
The live birth rate was 31.5% (288/915) in the overall population. Two hundred and twenty-six patients (24.7%) had a low serum P level, on the day of the FET. Univariate analysis showed that BMI (p < 0.001), parity (p = 0.001), non-European geographic origin (p = 0.001), and the duration of infertility (p = 0.018) were significantly associated with low serum P levels. Moreover, the proportion of active smokers was significantly lower in the “low P concentrations” group (p = 0.002). After multivariate analysis, BMI (OR 1.06 95%CI [1.02-1.11], p = 0.002), parity (OR 1.31 95%CI [1.04-1.65], p = 0.024), non-European geographic origin (OR 1.67 95%CI [1.19-2.35], p = 0.003), and active smoking (OR 0.43 95%CI [0.21-0.85], p = 0.016) remained independent factors associated with serum P levels ≤ 9.8 ng/mL.
Limitations, reasons for caution
The main limitation of our study is linked to its observational design. Extrapolation of our results to other laboratories, or other routes and/or doses of administering progesterone also needs to be validated.
Wider implications of the findings
There is urgent need for future research on clinical factors affecting P concentrations to help clinicians predicting which subgroups of patients would benefit from individualized luteal phase support. More data are also needed on the underlying mechanisms explaining the relationship between patients’ characteristics and serum P levels in HRT-cycles.
Trial registration number
NA
Collapse
Affiliation(s)
- C Maignien
- Hôpital Cochin Port Royal, Gynécologie Obstétrique II et Médecine de la Reproduction , Paris, France
| | - M Bourdon
- Hôpital Cochin Port Royal, Gynécologie Obstétrique II et Médecine de la Reproduction , Paris, France
| | - L Marcellin
- Hôpital Cochin Port Royal, Gynécologie Obstétrique II et Médecine de la Reproduction , Paris, France
| | - J Guibourdenche
- Hôpital Cochin Port Royal, Biological Endocrinology , Paris, France
| | - A Chargui
- Hôpital Cochin Port Royal, Histology and Reproductive Biology , Paris, France
| | - C Patrat
- Hôpital Cochin Port Royal, Histology and Reproductive Biology , Paris, France
| | - G Plu-Bureau
- Hôpital Cochin Port Royal, Gynécologie Obstétrique II et Médecine de la Reproduction , Paris, France
| | - C Chapron
- Hôpital Cochin Port Royal, Gynécologie Obstétrique II et Médecine de la Reproduction , Paris, France
| | - P Santulli
- Hôpital Cochin Port Royal, Gynécologie Obstétrique II et Médecine de la Reproduction , Paris, France
| |
Collapse
|
10
|
Bourdon M, Santulli P, Marcellin L, Maignien C, Maitrot-Mantelet L, Chapron C. [Adenomyosis pathophysiology: An unresolved enigma]. ACTA ACUST UNITED AC 2021; 50:182-188. [PMID: 34656788 DOI: 10.1016/j.gofs.2021.10.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2021] [Indexed: 11/25/2022]
Abstract
Adenomyosis is a chronic benign uterine disease characterized by the presence of endometrial glands and stroma within the myometrium. It is a heterogeneous disease, presenting various clinical forms, depending on the location of the ectopic lesions within the myometrium. Adenomyosis can be responsible for several symptoms such as dysmenorrhea, abnormal uterine bleeding and/or infertility. Its pathophysiology is a real conundrum and several theories have been proposed: development of adenomyosis lesion could initiate de novo from Mullerian rests or from stem cells. Moreover, multiple factors could be involved in initiating lesions, including specific hormonal, immune and/or genetic changes. The objective of this review is to provide an update on adenomyosis pathophysiology, in particular on the various theories proposed concerning the invasion of the myometrium by endometrial cells and the inducing mechanisms, and to study the link between the physiopathology, the symptoms and the medical treatments.
Collapse
Affiliation(s)
- M Bourdon
- Université de Paris, faculté de santé, faculté de médecine Paris Centre, Paris, France; Assistance publique-Hôpitaux de Paris (AP-HP), hôpital universitaire Paris Centre (HUPC), centre hospitalier universitaire (CHU) Cochin, département de gynécologie obstétrique II et médecine de la reproduction, Paris, France; Département 3I « infection, immunité et inflammation », Cochin Institute, INSERM U1016, Paris, France.
| | - P Santulli
- Université de Paris, faculté de santé, faculté de médecine Paris Centre, Paris, France; Assistance publique-Hôpitaux de Paris (AP-HP), hôpital universitaire Paris Centre (HUPC), centre hospitalier universitaire (CHU) Cochin, département de gynécologie obstétrique II et médecine de la reproduction, Paris, France; Département 3I « infection, immunité et inflammation », Cochin Institute, INSERM U1016, Paris, France
| | - L Marcellin
- Université de Paris, faculté de santé, faculté de médecine Paris Centre, Paris, France; Assistance publique-Hôpitaux de Paris (AP-HP), hôpital universitaire Paris Centre (HUPC), centre hospitalier universitaire (CHU) Cochin, département de gynécologie obstétrique II et médecine de la reproduction, Paris, France; Département 3I « infection, immunité et inflammation », Cochin Institute, INSERM U1016, Paris, France
| | - C Maignien
- Assistance publique-Hôpitaux de Paris (AP-HP), hôpital universitaire Paris Centre (HUPC), centre hospitalier universitaire (CHU) Cochin, département de gynécologie obstétrique II et médecine de la reproduction, Paris, France
| | - L Maitrot-Mantelet
- Assistance publique-Hôpitaux de Paris (AP-HP), hôpital universitaire Paris Centre (HUPC), centre hospitalier universitaire (CHU) Cochin, département de gynécologie obstétrique II et médecine de la reproduction, Paris, France
| | - C Chapron
- Université de Paris, faculté de santé, faculté de médecine Paris Centre, Paris, France; Assistance publique-Hôpitaux de Paris (AP-HP), hôpital universitaire Paris Centre (HUPC), centre hospitalier universitaire (CHU) Cochin, département de gynécologie obstétrique II et médecine de la reproduction, Paris, France; Département 3I « infection, immunité et inflammation », Cochin Institute, INSERM U1016, Paris, France
| |
Collapse
|
11
|
Maignien C, Mathilde B, Valérie B, Ahmed C, Charles C, Pietro S. P–404 Low serum progesterone on the day of frozen blastocyst transfer is associated with a diminished ongoing pregnancy rate in hormonal replacement therapy cycles. Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Study question
Is there a relationship between progesterone levels on the day of frozen blastocyst transfer and ongoing pregnancy rate (OPR), in hormonal replacement therapy (HRT) cycles?
Summary answer
Women undergoing HRT-frozen embryo transfer with progesterone levels≤9.76ng/ml on the day of blastocyst transfer had a significantly lower OPR than those with progesterone levels>9.76 ng/ml.
What is known already
The importance of serum progesterone levels around the time of frozen embryo transfer (FET) is a burning issue, in view of the growing number of FET worldwide. However, the optimal range of serum progesterone levels is not clearly determined and discrepancies arise from the current literature. Study design, size, duration: Observational cohort study with 915 patients undergoing HRT-FET at a tertiary care university hospital, between January 2019 and March 2020.
Participants/materials, setting, methods
Patients undergoing single autologous blastocyst FET under HRT using exogenous estradiol and vaginal micronized progesterone for endometrial preparation. Women were only included once during the study period. The serum progesterone level was measured in the morning of the FET, in a single laboratory. The primary endpoint was OPR beyond pregnancy week 12. Statistical analysis was conducted using univariate and multivariate logistic regression models.
Main results and the role of chance
Mean serum progesterone level on the day of FET was 12.90 ± 4.89 ng/ml). The OPR was 35.5% (325/915) in the overall population. Patients with a progesterone level ≤ 25th percentile (≤9.76ng/ml) had a significantly lower OPR and a higher miscarriage rate (MR) compared with women with progesterone level over Centile 25 (29.6% versus 37.4%; p = 0.033 and 34.8% versus 21.3%; p = 0.008, respectively). After adjustment for the potential confounders in a multivariate analysis, a serum progesterone level ≤ 9.76 ng/ml on the day of FETand FET of a Day 6-blastocyst (versus Day 5-blastocyst) were found as independent risks factor of lower OPR.
Limitations, reasons for caution
The main limitation of our study is linked to its observational design. Extrapolation of our results to other laboratories, or other routes and/or doses of administering progesterone also needs to be validated.
Wider implications of the findings: This study suggests that a minimum serum progesterone level is needed to optimize reproductive outcomes in autologous blastocyst FET, in HRT-cycles. Further studies are needed to evaluate if modifications of progesterone routes and/or doses may improve pregnancy chances, in an approach to individualize the management of ART patients.
Trial registration number
NA
Collapse
Affiliation(s)
- C Maignien
- Université de Paris- Faculté de Santé- Faculté de Médecine Paris Centre- 12 Rue de l’École de Médecine 75006 Paris- France, Department of Gynecology Obstetrics II and Reproductive Medicine Professor Chapron- Assistance Publique-Hôpitaux de Paris AP-HP
| | - B Mathilde
- Université de Paris- Faculté de Santé- Faculté de Médecine Paris Centre- 12 Rue de l’École de Médecine 75006 Paris- France, Department of Gynecology Obstetrics II and Reproductive Medicine Professor Chapron- Assistance Publique-Hôpitaux de Paris AP-HP
| | - B Valérie
- Université de Paris- Faculté de Santé- Faculté de Médecine Paris Centre- 12 Rue de l’École de Médecine 75006 Paris- France, Department of Gynecology Obstetrics II and Reproductive Medicine Professor Chapron- Assistance Publique-Hôpitaux de Paris AP-HP
| | - C Ahmed
- Université de Paris- Faculté de Santé- Faculté de Médecine Paris Centre- 12 Rue de l’École de Médecine 75006 Paris- France, Department of histology and Reproductive biology- Centre Hospitalier Universitaire CHU Cochin- Paris- France, Paris, France
| | - C Charles
- Université de Paris- Faculté de Santé- Faculté de Médecine Paris Centre- 12 Rue de l’École de Médecine 75006 Paris- France, Department of Gynecology Obstetrics II and Reproductive Medicine Professor Chapron- Assistance Publique-Hôpitaux de Paris AP-HP
| | - S Pietro
- Université de Paris- Faculté de Santé- Faculté de Médecine Paris Centre- 12 Rue de l’École de Médecine 75006 Paris- France, Department of Gynecology Obstetrics II and Reproductive Medicine Professor Chapron- Assistance Publique-Hôpitaux de Paris AP-HP
| |
Collapse
|
12
|
Santulli P, Bourdon M, Melka L, Bordonne C, Millisher AE, Maitrot-Mantelet L, Maignien C, Marcellin L, Chapron C. P–326 Presence of adenomyosis at MRI in endometriosis women negatively affect live birth chances in IVF cycles. Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Study question
What is the impact of adenomyosis and its magnetic resonance imaging (MRI) characteristics on live birth rate (LBR) in endometriosis-affected women undergoing in-vitro fertilization (IVF) treatment?
Summary answer
Among women undergoing IVF, the presence of adenomyosis at MRI, and especially T2 high signal-intensity spots within the myometrium have a negative impact on LBR. What is known already: Adenomyosis is a frequent gynecologic disease. With the development of imaging technics for the diagnosis (notably MRI), several adenomyosis phenotypes have been described and fertility issues seem variable according to the lesions characteristics. Moreover, on IVF outcomes, controversial results have been found in studies assessing the impact of adenomyosis. What make the impact-assessment of adenomyosis on fertility issues even more difficult is the frequent association with endometriosis, another known risk factor of infertility. Some data suggested that adenomyosis could worsen IVF prognostics, however there is no clear consensus about the impact of the adenomyosis on IVF outcomes in endometriosis affected-women.
Study design, size, duration
This was an observational study including phenotyped endometriosis patients, aged between 18 to 42 years, who underwent IVF/intra-cytoplasmic sperm injection (ICSI) treatment in a tertiary care center, from June 2015 through July 2018.Only women who had performed a pelvic MRI during the pre-therapeutic ART work-up, were retained for this study. The MRI data were interpreted by radiologists who had expertise in gynaecological MRI.
Participants/materials, setting, methods
A continuous series of 202 endometriosis affected women was included. The women were followed until four ART cycles had been completed, until delivery or until discontinuation of treatment before the completion of four cycles. The primary outcome was the delivery of one or more live infant(s) after up to four IVF/ICSI cycles. Patients and MRI characteristics were compared between women who gave a live birth and those without live birth.
Main results and the role of chance
The mean age of the included population was 32.5 ±3.7 years. 90.1% (182/202) had deep infiltrating endometriosis whereas only 5.4% (11/202) and 4.5% (9/202) had respectively isolated ovarian endometriosis (OMA) and superficial peritoneal endometriosis (SUP). The presence of adenomyosis (internal and/or external lesions) was found in 71.8% (145/202) of included women. The cumulative live birth rate was 57.4% (116/202). Women that gave birth (‘live birth +’) were significantly younger, (33.3±4.1 vs 32.0±3.3 p = 0.026) and had significant better ovarian reserve parameters (AMH, AFC). The presence of adenomyosis (internal and/or external lesions) (76/116 (65.5%) versus 69/86 (80.2%), p = 0.022) and the presence of T2 high-signal intensity myometrial spots (27/116 (23.3%) and 37/86 (43.0%), p = 0.003) were significantly less frequently found in the group of women ‘Live birth +’. After multivariate analysis, the presence of adenomyosis (OR: 0.48 95% CI (0.29–0.99) p = 0.048) and the presence of T2 high-signal intensity myometrial spots (OR: 0.43 95% CI (0.22–0.86) p = 0.018) were independently found to be associated with a decrease in cumulative chances of live birth.
Limitations, reasons for caution
The inclusion of patients from our referral center could constitute a possible selection bias, as those women may have suffered from particularly severe forms of adenomyosis ± endometriosis.
Wider implications of the findings: In women presenting endometriosis, the practitioner should perform an appropriate imaging work-up searching for adenomyosis, to identify prognostic factors and to plan the strategy of patient management in the setting of ART.
Trial registration number
NA
Collapse
Affiliation(s)
- P Santulli
- Cochin - Port Royal - Hôpitaux Universitaires Paris Centre-, Service de Gynécologie-obstétrique et médecine de la reproduction II, Paris, France
| | - M Bourdon
- Cochin - Port Royal - Hôpitaux Universitaires Paris Centre-, Service de Gynécologie-obstétrique et médecine de la reproduction II, Paris, France
| | - L Melka
- Cochin - Port Royal - Hôpitaux Universitaires Paris Centre-, Service de Gynécologie-obstétrique et médecine de la reproduction II, Paris, France
| | - C Bordonne
- Centre de radiologie Bachaumont, Radiology, Paris, France
| | - A E Millisher
- Centre de radiologie Bachaumont, Radiology, Paris, France
| | - L Maitrot-Mantelet
- Cochin - Port Royal - Hôpitaux Universitaires Paris Centre-, Service de Gynécologie-obstétrique et médecine de la reproduction II, Paris, France
| | - C Maignien
- Cochin - Port Royal - Hôpitaux Universitaires Paris Centre-, Service de Gynécologie-obstétrique et médecine de la reproduction II, Paris, France
| | - L Marcellin
- Cochin - Port Royal - Hôpitaux Universitaires Paris Centre-, Service de Gynécologie-obstétrique et médecine de la reproduction II, Paris, France
| | - C Chapron
- Cochin - Port Royal - Hôpitaux Universitaires Paris Centre-, Service de Gynécologie-obstétrique et médecine de la reproduction II, Paris, France
| |
Collapse
|
13
|
Legay L, Marcellin L, Santulli P, Millischer AE, Bordonne C, Maitrot Mantelet L, Maignien C, Bourdon M, Borghese B, Goffinet F, Chapron C. O-146 Assessment of focal and diffuse adenomyosis lesions before and after pregnancy on magnetic resonance imaging : a cohort of 139 patients. Hum Reprod 2021. [DOI: 10.1093/humrep/deab127.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Study question
How to assess the different adenomyosis phenotype before and after pregnancy on magnetic resonance imaging according to stringent validated criteria ?
Summary answer
Diffuse adenomyosis increases significantly after pregnancy while the rate of focal adenomyosis and the mean volume of focal adenomyosis lesions decrease significantly after pregnancy.
What is known already
Adenomyosis and endometriosis are benign hormone-dependent disorders associated with pelvic pain, dysmenorrhea and/or infertility. The natural course of adenomyosis and endometriosis is still unclear, particularly during pregnancy. Pregnancy is considered to have a positive impact on endometriosis. Several studies regarding the impact of adenomyosis on pregnancy are available. Adenomyosis can cause fertility disorders, miscarriage, preterm birth. However, available data evaluating the effect of pregnancy on adenomyosis are lacking.
Study design, size, duration
Between January 1st 2010 and September 30th 2020, 139 patients were followed in our referral care center (Gynecology department of Port-Royal Hospital, Paris) for symptomatic adenomyosis and or endometriosis. For each of them, a magnetic resonance imaging were performed before and after pregnancy. The data based on magnetic resonance imaging, pre- and post-pregnancy, were analyzed in a single retrospective study.
Participants/materials, setting, methods
Patients had to be over 18 years old, to be pregnant and to be followed for symptomatic adenomyosis or endometriosis without any previous surgery. Each pelvic magnetic resonance imaging were performed by a single experienced radiologist. The protocol was identical on a 1.5 T magnetic resonance imaging machine based on validated criteria. The rate of diffuse and focal adenomyosis, the volume of focal adenomyosis lesions and the thickness of maximal junctional zone were reported.
Main results and the role of chance
The mean age of patients was 34.6 ± 3.4 years old, 83 (59.7%) of patients underwent assisted reproductive technology to be pregnant. The mean time interval between the MRI and the delivery was 55.2 months and the mean time interval between the delivery and the MRI was 32.2 months. Before pregnancy, there was 96 (69.1%) patients with adenomyosis, all phenotype combined versus 111 (79.9%) after pregnancy (p = 0.04) on magnetic resonance imaging. The rate of diffuse adenomyosis increased significantly on magnetic resonance imaging after pregnancy compared to before pregnancy (n = 22 (15.8%) vs n = 41 (29.5%), p = 0.01). The thickness of junctional zone maximal was significantly higher after pregnancy (8.0 mm ± 5.1 vs 12.0 mm ± 4.8, p < 0.01). The rate of focal adenomyosis (n = 55 (39.6) vs n = 34 (24.5), p = 0.01) as well as the volume of focal adenomyosis lesions (6.7 mm3 2.5± vs 6.4 mm3 ± 2.3, p < 0.01) decreased significantly after pregnancy on magnetic resonance imaging.
Limitations, reasons for caution
This single-center study was conducted in a referral center whom patients presented more severe forms of adenomyosis, which could have affected the external validity of this study. The mean time interval between delivery and MRI was 32.2 month which implies a short follow up period to observe long term outcomes.
Wider implications of the findings
The hypothesis that a specific hormonal environment during pregnancy may imply a positively impact of the evolution of focal adenomyosis is raised by this study. The evolution of focal adenomyosis after pregnancy is similar to the evolution of endometriosis lesions volume that support shared etiopathogenic mechanisms between the two entities.
Trial registration number
‘not applicable’
Collapse
Affiliation(s)
- L Legay
- Hôpital Port Royal, gynecology, PARIS, France
| | - L Marcellin
- Hôpital Port Royal, gynecology, PARIS, France
| | - P Santulli
- Hôpital Port Royal, gynecology, PARIS, France
| | - A E Millischer
- Centre imagerie femme enfant - IMPC Bachaumont, radiology, Paris, France
| | - C Bordonne
- Hôpital Hôtel Dieu, radiology, Paris, France
| | | | - C Maignien
- Hôpital Port Royal, gynecology, PARIS, France
| | - M Bourdon
- Hôpital Port Royal, gynecology, PARIS, France
| | - B Borghese
- Hôpital Port Royal, gynecology, PARIS, France
| | - F Goffinet
- Hôpital Port Royal, gynecology, PARIS, France
| | - C Chapron
- Hôpital Port Royal, gynecology, PARIS, France
| |
Collapse
|
14
|
Maget AS, Bourdon M, Salle B, Patrat C, Maignien C, Marcellin L, Chapron C, Santulli P. P–453 Fertility preservation in endometriosis: Impact of the ovarian endometriosis and it’s surgical treatment on oocyte yield. Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Study question
Does a previous history of surgery for ovarian endometriosis (OMA) has an impact on controlled ovarian stimulation (COS) response in case of fertility preservation (FP) for endometriosis?
Summary answer
After COS, a prior history for OMA surgery was associated with poorer ovarian responsiveness compared to non-previously operated women.
What is known already
Endometriosis is a chronic disorder that affects 10% of woman, which can be responsible for infertility. The presence of OMA and/or it’s excision could induce a reduction of the ovarian reserve (ROR), and for some women, an increased risk of premature ovarian failure. Therefore, FP with oocyte/embryo vitrification can be proposed for OMA-affected women, considering the relationship between endometriosis, infertility and ROR. Although a complete surgery excision of endometriosis lesions may be appropriate for some patients to relieve them from pain, the more efficient time to preserve fertility is still unknown in the management of women presenting OMA lesions.
Study design, size, duration
We conducted an observational multicentric study from April 2015 to December 2019, in two tertiary care university hospitals. Women presenting OMA or having a previous history of surgery for OMA that had performed a FP with COS for oocytes/embryo vitrification during the study period were included. Diagnosis of endometriosis was based on published imaging criteria using transvaginal sonography and magnetic resonance imaging or histologically proven in women who had past surgery.
Participants/materials, setting, methods
A total of 165 women were allocated to two groups, according to the presence of a previous history of surgery for endometrioma(s). Main outcome measure was the total number of oocytes retrieved.
Main results and the role of chance
Fifty-one (30,9%) women were included in the group ‘previous history of surgery’ and 115 (69,1%) in the group ‘no history of surgery’. Mean age was 31,6±4,4 years and was not significantly different between groups (p = 0.09). However, women in ‘No previous surgery’ group had higher AMH levels than women in ‘previous surgery’ group (2.27±1.70ng/ml versus 1.56±1.89ng/ml; p < 0,001). In the group ‘previous history of surgery’, 21(41.2%) women had a recurrence of OMA(s) and 31 (60.8%) had at least one deep infiltrating endometriosis (DIE) lesion at FP. In the group ‘no history of surgery’, 92(80.7%) of the women had DIE. In addition, women in ‘No previous surgery group’ had larger OMA than women in ‘previous surgery’ group (mean diameter size: 5.56±4.34cm versus 3.25±2.16cm, respectively; p:0,03).
The mean number of COS with oocyte-retrieval was significantly higher in the group ‘previous history of surgery’ (2.0±1.02 versus 1.65±0.82 in the group ‘no surgery’, p = 0.03), however, the total number of oocytes retrieved per women was significantly higher in women ‘history of surgery’, compared to women ‘no previous surgery’ (13.7±8.4 versus 10.3±7.5, p = 0.02). In addition, the cancellation rate per cycle was significantly lower in ‘No previous surgery’ group compared to the ‘previous surgery’ group (0.09±0.31 versus 0.28±0.53; p < 0.001).
Limitations, reasons for caution
No data concerning the thawing of oocytes/embryo are available for now.
Wider implications of the findings: FP is an essential component to integrate in ovarian endometriosis-management and should be proposed before surgery to optimize oocyte yield.
Trial registration number
Not applicable
Collapse
Affiliation(s)
- A S Maget
- Hôpital Cochin, maternité Port Royal service de gynécologie obstétrique II, Paris, France
| | - M Bourdon
- Hopital Cochin, Maternité Port Royal service de gynécologie obstétrique II, Paris, France
| | - B Salle
- Hôpital mère enfant- Bron, Service de médecine de la reproduction, Lyon, France
| | - C Patrat
- Hôpital Cochin, Service de biologie de la reproduction, Paris, France
| | - C Maignien
- Hôpital Cochin, Maternité Port Royal- service de gynécologie obstétrique II, Paris, France
| | - L Marcellin
- Hôpital Cochin, Maternité Port Royal- service de gynécologie obstétrique II, Paris, France
| | - C Chapron
- Hôpital Cochin, Maternité Port Royal- service de gynécologie obstétrique II, Paris, France
| | - P Santulli
- Hôpital Cochin, Maternité Port Royal- service de gynécologie obstétrique II, Paris, France
| |
Collapse
|
15
|
Dahan Y, Bourdon M, Maignien C, Patrat C, Marcellin L, Chapron C, Santulli P. P–323 Ovarian response to stimulation according to endometrioma size, in women with deep infiltrating endometriosis – A comparative study. Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Study question
Does endometrioma (OMA) size affect the number of oocytes retrieved after ovarian stimulation (OS) in women with deep infiltrating endometriosis (DIE)? Summary answer: No significant difference in the number of oocytes retrieved was observed according to the endometrioma size.
What is known already
Ovarian endometriosis lesions (OMA) per se and above all, the surgical excision, appears to result in a risk of alteration of the ovarian reserve. In vitro fertilization (IVF) is a validated therapeutic option to treat infertility related to endometriosis. Nevertheless, it has been described that the presence of OMA could have a detrimental impact on ovarian responsiveness to hyperstimulation involving mechanisms still unclear. Some recent studies suggest that the size of the OMA may be relevant and that there may be a threshold in cyst diameter above which ovarian responsiveness might be affected. Study design, size, duration: This was an observational study using data prospectively collected in a cohort of infertile women aged between 18 and 43 years presenting OMA associated with DIE lesions, between December 2012 and July 2019. Every patient underwent their first in vitro fecundation or intracytoplasmic sperm injection (IVF/ICSI) cycle. Included women were women with an adequate imaging work up with Transvaginal ultrasound and/or magnetic resonance imaging (TVUS/MRI) performed by senior radiologists before the beginning of the OS.
Participants/materials, setting, methods
One hundred and eighty-two women were included in the study. Women were allocated in 5 groups according to the largest diameter of their ovarian endometriosis lesions: OMA < 2 cm, 2 cm ≤ OMA < 4 cm, 4 cm ≤ OMA < 6 cm, 6 cm ≤ OMA < 8 cm, OMA ≥ 8 cm. The main outcome was the number of oocytes retrieved.
Main results and the role of chance
Mean age of the included women was 32.8 years. 96(52.7%) women had unilateral endometrioma and 86 (47.3%) had bilateral endometriomas. The mean OMA size was 3.63 cm for right ovary and 3.60 cm for left ovary. Considering the largest diameter of OMA retained, the mean size was 4.12 cm. Repartition among groups, according to the size of the largest OMA diameter was: OMA < 2cm group (n = 32); 2 £OMA< 4 cm (n = 70); 4 £OMA< 6 cm, (n = 37); 6 £OMA< 8 cm (n = 27); OMA8 cm (n = 16).
Mean number of oocytes retrieved was not significantly different between groups (p = 0.635): 8.4±5.7 for OMA< 2 cm, 7.3 ± 5.4 for 2 cm≤OMA<4 cm, 6.6 ± 3.9 for 4 cm≤OMA< 6 cm, 8.6 ± 5.8 for 6 cm ≤OMA<8 cm and 7.1 ± 3.6 for OMA≥8 cm. Mean number of matures oocytes was also comparable between groups (p = 0.674). Clinical pregnancy rate and live birth rate was similar between groups (p = 0.798 and p = 0.913). No significant difference was found concerning the number of cancelled cycles between groups (p = 0.703).
Limitations, reasons for caution
For almost half of the included women, endometriosis diagnosis was based on imaging technics, without histological proof of endometriosis. However, it was performed by specialized seniors radiologists.
Wider implications of the findings: Our study suggests that whatever endometrioma size, OS can be benefit for women with endometrioma, even for largest ones, without the requirement of prior treatment to reduce their size
Trial registration number
NA
Collapse
Affiliation(s)
- Y Dahan
- Hôpital Cochin, Maternité Port Royal - Service de gynécologie obstétrique II, Paris, France
| | - M Bourdon
- Hôpital Cochin, Maternité Port Royal - Service de gynécologie obstétrique II, Paris, France
| | - C Maignien
- Hôpital Cochin, Maternité Port Royal - Service de gynécologie obstétrique II, Paris, France
| | - C Patrat
- Hôpital Cochin, Maternité Port Royal - Service de biologie de la reproduction, Paris, France
| | - L Marcellin
- Hôpital Cochin, Maternité Port Royal - Service de gynécologie obstétrique II, Paris, France
| | - C Chapron
- Hôpital Cochin, Maternité Port Royal - Service de gynécologie obstétrique II, Paris, France
| | - P Santulli
- Hôpital Cochin, Maternité Port Royal - Service de gynécologie obstétrique II, Paris, France
| |
Collapse
|
16
|
Millischer AE, Marcellin L, Santulli P, Maignien C, Bourdon M, Borghese B, Goffinet F, Chapron C. Magnetic resonance imaging presentation of deep infiltrating endometriosis nodules before and after pregnancy: A case series. PLoS One 2019; 14:e0223330. [PMID: 31584969 PMCID: PMC6777797 DOI: 10.1371/journal.pone.0223330] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2019] [Accepted: 09/18/2019] [Indexed: 12/12/2022] Open
Abstract
OBJECTIVE To compare the magnetic resonance imaging (MRI) features of deep infiltrating endometriosis (DIE) lesions before and after pregnancy. DESIGN Retrospective study. SETTING A single French university tertiary referral hospital. PATIENTS Twenty-one women without a prior history of surgery for endometriosis with a radiological diagnosis by MRI with two sets of examinations performed before and after pregnancy. INTERVENTIONS The volumes of the lesions were compared using the same protocol before and after pregnancy based on MRI (1.5 T) examinations by a single experienced radiologist who is a referring practitioner for image-based diagnosis of endometriosis. MAIN OUTCOME MEASURE(S) The DIE lesion volume. MEASUREMENTS AND MAIN RESULTS Between October 2012 and December 2016, a total of 21 patients (67 lesions) were included and compared before and after pregnancy. The mean time interval between the MRI before pregnancy and delivery was 19.6 ± 8.5 months (median: 17.6, IQR 13.5-25.2 months). The mean time interval between delivery and the MRI after pregnancy was 11.0 ± 6.4 months (median: 8.3, IQR 6-15.2 months). The mean overall DIE lesion volume by MRI was significantly higher before pregnancy compared to after pregnancy (2,552 ± 3,315 mm3 vs. 1,708 ± 3,266 mm3, respectively, p < 0.01). The mean volume by MRI of the largest lesion of each patient was significantly higher before pregnancy compared to after pregnancy (4,728 ± 4,776 mm3 vs. 3165 ± 5299 mm3; p < 0.01). CONCLUSION Our data indicate a favorable impact of pregnancy on DIE lesion volumes as measured by MRI.
Collapse
Affiliation(s)
- Anne Elodie Millischer
- Centre de Radiologie IMPC Bachaumont Pole femme-mere-enfant, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Assistance Publique–Hôpitaux de Paris (AP-HP), Service de Chirurgie Gynécologie Obstétrique II et Médecine de la Reproduction, Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
- * E-mail:
| | - Louis Marcellin
- Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Assistance Publique–Hôpitaux de Paris (AP-HP), Service de Chirurgie Gynécologie Obstétrique II et Médecine de la Reproduction, Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
- Equipe Stress Oxydant, Prolifération Cellulaire et Inflammation, Département Développement, Reproduction, Cancer, Inserm U1016, Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, AP-HP, HUPC, CHU Cochin, Paris, France
| | - Pietro Santulli
- Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Assistance Publique–Hôpitaux de Paris (AP-HP), Service de Chirurgie Gynécologie Obstétrique II et Médecine de la Reproduction, Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
- Equipe Stress Oxydant, Prolifération Cellulaire et Inflammation, Département Développement, Reproduction, Cancer, Inserm U1016, Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, AP-HP, HUPC, CHU Cochin, Paris, France
| | - Chloe Maignien
- Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Assistance Publique–Hôpitaux de Paris (AP-HP), Service de Chirurgie Gynécologie Obstétrique II et Médecine de la Reproduction, Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
- Equipe Stress Oxydant, Prolifération Cellulaire et Inflammation, Département Développement, Reproduction, Cancer, Inserm U1016, Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, AP-HP, HUPC, CHU Cochin, Paris, France
| | - Mathilde Bourdon
- Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Assistance Publique–Hôpitaux de Paris (AP-HP), Service de Chirurgie Gynécologie Obstétrique II et Médecine de la Reproduction, Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
- Equipe Stress Oxydant, Prolifération Cellulaire et Inflammation, Département Développement, Reproduction, Cancer, Inserm U1016, Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, AP-HP, HUPC, CHU Cochin, Paris, France
| | - Bruno Borghese
- Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Assistance Publique–Hôpitaux de Paris (AP-HP), Service de Chirurgie Gynécologie Obstétrique II et Médecine de la Reproduction, Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
- Equipe Génomique, Epigénétique et Physiopathologie de la Reproduction, Département Développement, Reproduction, Cancer, Inserm U1016, Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, AP-HP, HUPC, CHU Cochin, Paris, France
| | - François Goffinet
- Port Royal Maternity Unit, Cochin Hospital, Assistance Publique des Hôpitaux de Paris, DHU Risks and Pregnancy, Paris Descartes University, Paris, France
| | - Charles Chapron
- Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Assistance Publique–Hôpitaux de Paris (AP-HP), Service de Chirurgie Gynécologie Obstétrique II et Médecine de la Reproduction, Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Paris, France
- Equipe Génomique, Epigénétique et Physiopathologie de la Reproduction, Département Développement, Reproduction, Cancer, Inserm U1016, Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, AP-HP, HUPC, CHU Cochin, Paris, France
| |
Collapse
|
17
|
Santulli P, Tran C, Gayet V, Bourdon M, Maignien C, Marcellin L, Pocate-Cheriet K, Chapron C, de Ziegler D. Oligo-anovulation is not a rarer feature in women with documented endometriosis. Fertil Steril 2019; 110:941-948. [PMID: 30316441 DOI: 10.1016/j.fertnstert.2018.06.012] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2017] [Revised: 06/06/2018] [Accepted: 06/07/2018] [Indexed: 11/17/2022]
Abstract
OBJECTIVE To study the prevalence of oligo-anovulation in women suffering from endometriosis compared to that of women without endometriosis. DESIGN A single-center, cross-sectional study. SETTING University hospital-based research center. PATIENT (S) We included 354 women with histologically proven endometriosis and 474 women in whom endometriosis was surgically ruled out between 2004 and 2016. INTERVENTION None. MAIN OUTCOME MEASURE(S) Frequency of oligo-anovulation in women with endometriosis as compared to that prevailing in the disease-free reference group. RESULTS There was no difference in the rate of oligo-anovulation between women with endometriosis (15.0%) and the reference group (11.2%). Regarding the endometriosis phenotype, oligo-anovulation was reported in 12 (18.2%) superficial peritoneal endometriosis, 12 (10.6%) ovarian endometrioma, and 29 (16.6%) deep infiltrating endometriosis. CONCLUSION(S) Endometriosis should not be discounted in women presenting with oligo-anovulation.
Collapse
Affiliation(s)
- Pietro Santulli
- Department of Gynaecology Obstetrics II and Reproductive Medicine, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre, Centre Hospitalier Universitaire (CHU) Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Department of Development, Reproduction and Cancer, Institut Cochin, INSERM U1016, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Chloe Tran
- Department of Gynaecology Obstetrics II and Reproductive Medicine, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre, Centre Hospitalier Universitaire (CHU) Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Vanessa Gayet
- Department of Gynaecology Obstetrics II and Reproductive Medicine, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre, Centre Hospitalier Universitaire (CHU) Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Mathilde Bourdon
- Department of Gynaecology Obstetrics II and Reproductive Medicine, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre, Centre Hospitalier Universitaire (CHU) Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Department of Development, Reproduction and Cancer, Institut Cochin, INSERM U1016, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Chloe Maignien
- Department of Gynaecology Obstetrics II and Reproductive Medicine, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre, Centre Hospitalier Universitaire (CHU) Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Louis Marcellin
- Department of Gynaecology Obstetrics II and Reproductive Medicine, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre, Centre Hospitalier Universitaire (CHU) Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Department of Development, Reproduction and Cancer, Institut Cochin, INSERM U1016, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Khaled Pocate-Cheriet
- Department of Development, Reproduction and Cancer, Institut Cochin, INSERM U1016, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Charles Chapron
- Department of Gynaecology Obstetrics II and Reproductive Medicine, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre, Centre Hospitalier Universitaire (CHU) Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Department of Development, Reproduction and Cancer, Institut Cochin, INSERM U1016, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Dominique de Ziegler
- Department of Gynaecology Obstetrics II and Reproductive Medicine, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre, Centre Hospitalier Universitaire (CHU) Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
| |
Collapse
|
18
|
Bourdon M, Santulli P, Marcellin L, Lamau MC, Maignien C, Chapron C. [Bowel endometriosis and infertility: Do we need to operate?]. ACTA ACUST UNITED AC 2017; 45:486-490. [PMID: 28864051 DOI: 10.1016/j.gofs.2017.07.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2017] [Accepted: 07/11/2017] [Indexed: 10/18/2022]
Abstract
Endometriosis is a benign chronic inflammatory disease, whose pathogenesis is still unclear. Endometriosis is responsible for infertility and/or pelvic pain. One of the most important features of the disease is the heterogeneity (clinical and anatomical: superficial peritoneal, ovarian and/or deep infiltrating lesions). Bowel involvement constitutes one particularly severe form of the disease, affecting 8-12% of women with deep endometriosis. In case of associated infertility, bowel endometriosis constitutes a real therapeutic challenge for gynecologists. Indeed, while complete resection of the lesions alleviates pain and seems to improve spontaneous fertility, surgery remains technically challenging and may cause severe complications. Reverting to assisted Reproductive Technology (ART) is another valuable therapeutic option regarding pregnancy rates. Thus, the choice between surgical management or ART is still debated. Benefits and risks of these two options should be considered and discussed before planning treatment. In the present study, we aimed to answer the question: Bowel endometriosis and infertility: do we need to operate?
Collapse
Affiliation(s)
- M Bourdon
- Div. Reproductive Endocrine and Infertility, Department of Gynecology Obstetrics II and Reproductive Medicine, faculté de médecine, université Paris Descartes, Sorbonne Paris Cité, hôpital universitaire Paris centre (HUPC), centre hospitalier universitaire (CHU) Cochin, Assistance publique-hôpitaux de Paris (AP-HP), bâtiment Port-Royal, 53, avenue de l'Observatoire, 75679 Paris 14, France; Inserm U1016, Department "Development, Reproduction and Cancer", institut Cochin, université Paris Descartes, Sorbonne Paris Cité, 75679 Paris 14, France
| | - P Santulli
- Div. Reproductive Endocrine and Infertility, Department of Gynecology Obstetrics II and Reproductive Medicine, faculté de médecine, université Paris Descartes, Sorbonne Paris Cité, hôpital universitaire Paris centre (HUPC), centre hospitalier universitaire (CHU) Cochin, Assistance publique-hôpitaux de Paris (AP-HP), bâtiment Port-Royal, 53, avenue de l'Observatoire, 75679 Paris 14, France; Inserm U1016, Department "Development, Reproduction and Cancer", institut Cochin, université Paris Descartes, Sorbonne Paris Cité, 75679 Paris 14, France; Inserm U1016, Department "Development, Reproduction and Cancer", institut Cochin, université Paris Descartes, Sorbonne Paris Cité, Paris, France.
| | - L Marcellin
- Div. Reproductive Endocrine and Infertility, Department of Gynecology Obstetrics II and Reproductive Medicine, faculté de médecine, université Paris Descartes, Sorbonne Paris Cité, hôpital universitaire Paris centre (HUPC), centre hospitalier universitaire (CHU) Cochin, Assistance publique-hôpitaux de Paris (AP-HP), bâtiment Port-Royal, 53, avenue de l'Observatoire, 75679 Paris 14, France; Inserm U1016, Department "Development, Reproduction and Cancer", institut Cochin, université Paris Descartes, Sorbonne Paris Cité, 75679 Paris 14, France; Inserm U1016, Department "Development, Reproduction and Cancer", institut Cochin, université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - M C Lamau
- Div. Reproductive Endocrine and Infertility, Department of Gynecology Obstetrics II and Reproductive Medicine, faculté de médecine, université Paris Descartes, Sorbonne Paris Cité, hôpital universitaire Paris centre (HUPC), centre hospitalier universitaire (CHU) Cochin, Assistance publique-hôpitaux de Paris (AP-HP), bâtiment Port-Royal, 53, avenue de l'Observatoire, 75679 Paris 14, France
| | - C Maignien
- Div. Reproductive Endocrine and Infertility, Department of Gynecology Obstetrics II and Reproductive Medicine, faculté de médecine, université Paris Descartes, Sorbonne Paris Cité, hôpital universitaire Paris centre (HUPC), centre hospitalier universitaire (CHU) Cochin, Assistance publique-hôpitaux de Paris (AP-HP), bâtiment Port-Royal, 53, avenue de l'Observatoire, 75679 Paris 14, France
| | - C Chapron
- Div. Reproductive Endocrine and Infertility, Department of Gynecology Obstetrics II and Reproductive Medicine, faculté de médecine, université Paris Descartes, Sorbonne Paris Cité, hôpital universitaire Paris centre (HUPC), centre hospitalier universitaire (CHU) Cochin, Assistance publique-hôpitaux de Paris (AP-HP), bâtiment Port-Royal, 53, avenue de l'Observatoire, 75679 Paris 14, France; Inserm U1016, Department "Development, Reproduction and Cancer", institut Cochin, université Paris Descartes, Sorbonne Paris Cité, 75679 Paris 14, France; Inserm U1016, Department "Development, Reproduction and Cancer", institut Cochin, université Paris Descartes, Sorbonne Paris Cité, Paris, France
| |
Collapse
|
19
|
Benchabane M, Santulli P, Maignien C, Bourdon M, De Ziegler D, Chapron C, Gayet V. [Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for oocyte donors]. ACTA ACUST UNITED AC 2017; 45:83-88. [PMID: 28368800 DOI: 10.1016/j.gofs.2016.12.022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2016] [Accepted: 11/29/2016] [Indexed: 11/26/2022]
Abstract
OBJECTIVES To demonstrate that corifollitropin alfa is as effective as daily FSH in controlled ovarian stimulation of oocyte donors. METHODS From January 2013 to October 2015, 77 cycles controlled ovarian stimulation, derived from a continuous cohort of 77 oocyte donors, were analyzed. After synchronization by oestroprogestatif or estrogens, ovarian stimulation was started by corifollitropin alfa (Group corifollitropin alfa) or by daily FSH (Group daily FSH). In both groups, a GnRH antagonist was used for the prevention of premature surge of luteinizing hormone (LH). The induction of ovulation was induced by a GnRH agonist. The duration of treatment, estradiol rate, numbers of mature oocytes, fertilization rate, clinical and ongoing pregnancies rates were evaluated in the two groups. RESULTS There is no difference for the age, the markers of ovarian reserve and the duration of treatment. The average rate of estradiol on the eighth day of the stimulation is lower for the corifollitropin alfa (845±694.5 vs 1742±1177.3, P<0.001), there is no difference in the number of mature oocytes retrieved (14.4 vs 13.4, P=0.979), with a fertilization rate significantly higher in the corifollitropin alfa group (59.8% vs 49.3%, P<0.001). The rate of ongoing pregnancies is higher but without reaching significant difference in this same group (36.6% vs 26%, P=0.277). CONCLUSION As compared to daily FSH, corifollitropin alfa, in oocyte donors offers, advantages in terms of ease of use with identical efficiency.
Collapse
Affiliation(s)
- M Benchabane
- Department of gynaecology obstetrics II and reproductive medicine Paris, faculté de médecine, hôpital universitaire Paris centre, université Paris Descartes, Sorbonne Paris Cité, centre hospitalier universitaire (CHU) Cochin, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - P Santulli
- Department of gynaecology obstetrics II and reproductive medicine Paris, faculté de médecine, hôpital universitaire Paris centre, université Paris Descartes, Sorbonne Paris Cité, centre hospitalier universitaire (CHU) Cochin, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France; Institut Cochin, Inserm U1016, laboratoire d'immunologie, université Paris Descartes, Sorbonne Paris Cité, Paris, France; Institut Cochin, Inserm U1016, département de « génetique, développement et cancer », université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - C Maignien
- Department of gynaecology obstetrics II and reproductive medicine Paris, faculté de médecine, hôpital universitaire Paris centre, université Paris Descartes, Sorbonne Paris Cité, centre hospitalier universitaire (CHU) Cochin, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - M Bourdon
- Department of gynaecology obstetrics II and reproductive medicine Paris, faculté de médecine, hôpital universitaire Paris centre, université Paris Descartes, Sorbonne Paris Cité, centre hospitalier universitaire (CHU) Cochin, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - D De Ziegler
- Department of gynaecology obstetrics II and reproductive medicine Paris, faculté de médecine, hôpital universitaire Paris centre, université Paris Descartes, Sorbonne Paris Cité, centre hospitalier universitaire (CHU) Cochin, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - C Chapron
- Department of gynaecology obstetrics II and reproductive medicine Paris, faculté de médecine, hôpital universitaire Paris centre, université Paris Descartes, Sorbonne Paris Cité, centre hospitalier universitaire (CHU) Cochin, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France; Institut Cochin, Inserm U1016, laboratoire d'immunologie, université Paris Descartes, Sorbonne Paris Cité, Paris, France; Institut Cochin, Inserm U1016, département de « génetique, développement et cancer », université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - V Gayet
- Department of gynaecology obstetrics II and reproductive medicine Paris, faculté de médecine, hôpital universitaire Paris centre, université Paris Descartes, Sorbonne Paris Cité, centre hospitalier universitaire (CHU) Cochin, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France.
| |
Collapse
|
20
|
Santulli P, Somigliana E, Bourdon M, Maignien C, Marcellin L, Gayet V, Chapron C. [Conservative management of endometrioma in women undergoing in vitro fertilization]. J Gynecol Obstet Hum Reprod 2017; 46:203-209. [PMID: 28403916 DOI: 10.1016/j.jogoh.2016.09.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2016] [Revised: 09/10/2016] [Accepted: 09/29/2016] [Indexed: 11/15/2022]
Abstract
Endometriosis is a chronic disease. The pathogenesis is actually still unclear. Endometriosis is responsible for infertility and/or pelvic pain. One of the most important features of the disease is the heterogeneity (clinical and anatomical). Among the different phenotypes of endometriosis, the ovarian endometrioma seems to most important lesion in the management of endometriosis-related infertility. Surgical treatment is associated to a decrease of the ovarian reserve and a potential detrimental effect on in vitro fecondation (IVF) outcomes. Thus, the choice between conservative or surgical management of endometrioma before IVF is actually debated. The advantages and drawback of surgical and conservative management should be discussed before to plan the treatment. In the present review, we aimed at assessing the risks of a conservative management of endometrioma as compared to surgery before IVF.
Collapse
Affiliation(s)
- P Santulli
- Service de gynécologie-obstétrique II et médecine de la reproduction, hôpital universitaire Paris Centre, centre hospitalier universitaire (CHU) Cochin, Assistance publique-Hôpitaux de Paris (AP-HP), faculté de médecine, université Paris Descartes, Sorbonne Paris Cité, bâtiment Port Royal, 53, avenue de l'Observatoire, 75679 Paris 14, France; Inserm U1016, laboratoire d'immunologie, institut Cochin, université Paris Descartes, Sorbonne Paris Cité, Paris 14, France; Inserm U1016, département de génétique, développement et cancer, institut Cochin, université Paris Descartes, Sorbonne Paris Cité, Paris 14, France.
| | - E Somigliana
- Fondazione Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italie
| | - M Bourdon
- Service de gynécologie-obstétrique II et médecine de la reproduction, hôpital universitaire Paris Centre, centre hospitalier universitaire (CHU) Cochin, Assistance publique-Hôpitaux de Paris (AP-HP), faculté de médecine, université Paris Descartes, Sorbonne Paris Cité, bâtiment Port Royal, 53, avenue de l'Observatoire, 75679 Paris 14, France; Inserm U1016, laboratoire d'immunologie, institut Cochin, université Paris Descartes, Sorbonne Paris Cité, Paris 14, France
| | - C Maignien
- Service de gynécologie-obstétrique II et médecine de la reproduction, hôpital universitaire Paris Centre, centre hospitalier universitaire (CHU) Cochin, Assistance publique-Hôpitaux de Paris (AP-HP), faculté de médecine, université Paris Descartes, Sorbonne Paris Cité, bâtiment Port Royal, 53, avenue de l'Observatoire, 75679 Paris 14, France
| | - L Marcellin
- Service de gynécologie-obstétrique II et médecine de la reproduction, hôpital universitaire Paris Centre, centre hospitalier universitaire (CHU) Cochin, Assistance publique-Hôpitaux de Paris (AP-HP), faculté de médecine, université Paris Descartes, Sorbonne Paris Cité, bâtiment Port Royal, 53, avenue de l'Observatoire, 75679 Paris 14, France; Inserm U1016, laboratoire d'immunologie, institut Cochin, université Paris Descartes, Sorbonne Paris Cité, Paris 14, France; Inserm U1016, département de génétique, développement et cancer, institut Cochin, université Paris Descartes, Sorbonne Paris Cité, Paris 14, France
| | - V Gayet
- Service de gynécologie-obstétrique II et médecine de la reproduction, hôpital universitaire Paris Centre, centre hospitalier universitaire (CHU) Cochin, Assistance publique-Hôpitaux de Paris (AP-HP), faculté de médecine, université Paris Descartes, Sorbonne Paris Cité, bâtiment Port Royal, 53, avenue de l'Observatoire, 75679 Paris 14, France
| | - C Chapron
- Service de gynécologie-obstétrique II et médecine de la reproduction, hôpital universitaire Paris Centre, centre hospitalier universitaire (CHU) Cochin, Assistance publique-Hôpitaux de Paris (AP-HP), faculté de médecine, université Paris Descartes, Sorbonne Paris Cité, bâtiment Port Royal, 53, avenue de l'Observatoire, 75679 Paris 14, France; Inserm U1016, département de génétique, développement et cancer, institut Cochin, université Paris Descartes, Sorbonne Paris Cité, Paris 14, France
| |
Collapse
|
21
|
Maignien C, Marcellin L, Anselem O, Silvera S, Dousset B, Grangé G, Goffinet F. [Embolization of a ruptured pseudo-aneurysm of the uterine artery at 26weeks of gestation: Materno-fetal consequences; a case-report]. ACTA ACUST UNITED AC 2014; 44:665-9. [PMID: 25201019 DOI: 10.1016/j.jgyn.2014.07.005] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2014] [Revised: 06/27/2014] [Accepted: 07/08/2014] [Indexed: 11/28/2022]
Abstract
Rupture of a uterine artery pseudo-aneurysm during pregnancy is a rare condition with potential life-threatening complications, and management should take into account the fetal impact of the therapeutic choice. We report the case of a 2cm left uterine artery pseudo-aneurysm revealed by pelvic pain, in a 30-year-old pregnant woman at 26(+0)weeks of gestation (WG). Diagnosis was suspected at ultrasound scan, and confirmed with Magnetic Resonance angiography that showed signs of pre-rupture. An emergency selective embolization attempted in utero allowed the complete exclusion of the aneurysmal sac. The patient gave birth one month later to a girl at 31(+1)WG, initially managed by neonatologists, who is currently in good health.
Collapse
Affiliation(s)
- C Maignien
- Maternité Port-Royal, hôpital Cochin Broca, Hôtel-Dieu, Assistance publique-Hôpitaux de Paris, 53, avenue de l'Observatoire, 75014 Paris, France; DHU risques et grossesse, université Paris Descartes, Sorbonne Paris-Cité, 12, rue de l'École-de-Médecine, 75006 Paris, France.
| | - L Marcellin
- Maternité Port-Royal, hôpital Cochin Broca, Hôtel-Dieu, Assistance publique-Hôpitaux de Paris, 53, avenue de l'Observatoire, 75014 Paris, France; DHU risques et grossesse, université Paris Descartes, Sorbonne Paris-Cité, 12, rue de l'École-de-Médecine, 75006 Paris, France
| | - O Anselem
- Maternité Port-Royal, hôpital Cochin Broca, Hôtel-Dieu, Assistance publique-Hôpitaux de Paris, 53, avenue de l'Observatoire, 75014 Paris, France; DHU risques et grossesse, université Paris Descartes, Sorbonne Paris-Cité, 12, rue de l'École-de-Médecine, 75006 Paris, France
| | - S Silvera
- Service de radiologie, hôpital Cochin Broca, Hôtel-Dieu, Assistance publique-Hôpitaux de Paris, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France; DHU risques et grossesse, université Paris Descartes, Sorbonne Paris-Cité, 12, rue de l'École-de-Médecine, 75006 Paris, France
| | - B Dousset
- Service de chirurgie digestive, hépatobiliaire et endocrinienne, hôpital Cochin Broca, Hôtel-Dieu, Assistance publique-Hôpitaux de Paris, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France
| | - G Grangé
- Maternité Port-Royal, hôpital Cochin Broca, Hôtel-Dieu, Assistance publique-Hôpitaux de Paris, 53, avenue de l'Observatoire, 75014 Paris, France; DHU risques et grossesse, université Paris Descartes, Sorbonne Paris-Cité, 12, rue de l'École-de-Médecine, 75006 Paris, France
| | - F Goffinet
- Maternité Port-Royal, hôpital Cochin Broca, Hôtel-Dieu, Assistance publique-Hôpitaux de Paris, 53, avenue de l'Observatoire, 75014 Paris, France; DHU risques et grossesse, université Paris Descartes, Sorbonne Paris-Cité, 12, rue de l'École-de-Médecine, 75006 Paris, France
| |
Collapse
|